Two more pharmas practice their Accent, invest in $75M series C round

2024-01-23
引进/卖出
Two more pharmas practice their Accent, invest in $75M series C round
Preview
来源: FierceBiotech
Accent's $75 million series C included the first public investment from Mirae Asset Capital Life Science.
Accent Therapeutics has reeled in investments from two more pharmaceutical companies as part of a $75M series C, the latest validation for the RNA drug developer.
Bristol Myers Squibb and Johnson & Johnson’s investment arm, JJDC, participated in the funding round that was announced Tuesday, which was led by the recently launched Mirae Asset Capital Life Science. The two pharmas join AbbVie’s venture arm which had previously participated in the biotech's series B.
Accent CEO Shakti Narayan, Ph.D., said the money will help drive further development of the company’s two lead small molecules, targeting DHX9 and KIF18A, respectively. Accent’s plan is to formally ask regulators to enter human trials for both programs before the end of the year and put each in phase 1 studies by early 2025.
The three pharma backers come in addition to Accent’s existing research and licensing collaboration with AstraZeneca, announced in 2020. That gave the British pharma the option to a preclinical program that Accent would develop through phase 1 studies, plus worldwide licensing rights to two additional preclinical assets should AstraZeneca want more. Narayan wouldn’t specify which programs in the pipeline, if any, were assigned to AstraZeneca, saying only that the two lead programs were wholly owned.
All told, Narayan says the attention shows that Big Pharma “is excited about our story [and] is excited about the programs we're driving forward.”
“Together with our collaboration with AstraZeneca, there's just a great sense of endorsement and engagement from Big Pharma around our strategy and our vision,” he said.
The DHX9 asset has the potential to be first-in-class, but the KIF18A program is lagging slightly behind Volastra Therapeutics, which has two such assets in the clinic, one of which the biotech snagged from Amgen. Naveen Krishnan, M.D., managing director of Mirae Asset Capital’s new life science fund and incoming Accent board member, said Accent could gain from Volastra’s learnings.
Accent had a unique approach for how they're pursuing their KIF18 asset that to me, really focuses on widening that therapeutic index,” Krishnan said. “And I think there's certainly room for more than one player, particularly in KIF18A.”
Accent marks the first public investment for Kirshnan and Mirae’s new life science arm, which was unveiled last week with $50 million to spend. Krishnan, who took the reins after more than two years at Leaps by Bayer, expects the fund to make up to eight investments this year. He and the firm are already finalizing plans to participate in another unnamed biotech’s financing.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。